Intracellular drug measurements to predict toxicity in high-dose methotrexate therapy in leukaemia and central nervous system lymphoma: a pilot study

Intracellular drug measurements to predict toxicity in high-dose methotrexate therapy in leukaemia and central nervous system lymphoma: a pilot study - HAL study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47317

Enrollment

Registered

2015-12-17

Start date

2015-11-01

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bloed- en Lymfestelsel aandoeningen: leukemiën leukaemia and central nervous system lymphoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - All adult patients treated in the Erasmus MC with HD-MTX for a CNS lymphoma or ALL - Written informed consent

Exclusion criteria

Exclusion criteria: age

Design outcomes

Primary

Measure	Time frame
intracellulair MTX levels (polyglutamates)	—

Secondary

Measure	Time frame
toxicity	—

Countries

Netherlands

Outcome results